CYCC – cyclacel pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Form 8-K Cyclacel Pharmaceuticals For: Jan 02
Form 8-K Cyclacel Pharmaceuticals For: Dec 06
Form D Cyclacel Pharmaceuticals
Form 8-K Cyclacel Pharmaceuticals For: Nov 13
Form SC 13G/A Cyclacel Pharmaceuticals Filed by: Lind Global Fund II LP
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.